Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Amortization of Deferred Charges (2020 - 2023)

RxSight filings provide 4 years of Amortization of Deferred Charges readings, the most recent being $4000.0 for Q3 2023.

  • On a quarterly basis, Amortization of Deferred Charges fell 97.2% to $4000.0 in Q3 2023 year-over-year; TTM through Jun 2024 was $4000.0, a 99.3% decrease, with the full-year FY2023 number at $287000.0, down 48.01% from a year prior.
  • Amortization of Deferred Charges hit $4000.0 in Q3 2023 for RxSight, down from $142000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $465000.0 in Q4 2021 to a low of -$201000.0 in Q3 2021.
  • Median Amortization of Deferred Charges over the past 4 years was $132500.0 (2022), compared with a mean of $118083.3.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 447.06% in 2021 and later plummeted 97.2% in 2023.
  • RxSight's Amortization of Deferred Charges stood at $85000.0 in 2020, then soared by 447.06% to $465000.0 in 2021, then plummeted by 69.03% to $144000.0 in 2022, then tumbled by 97.22% to $4000.0 in 2023.
  • The last three reported values for Amortization of Deferred Charges were $4000.0 (Q3 2023), $142000.0 (Q2 2023), and $141000.0 (Q1 2023) per Business Quant data.